Cargando…
Resistance to Immunotherapeutic Antibodies in Cancer Strategies to Overcome Resistance /
The current application of antibody-meditated targeted therapy against cancer has resulted in significant objective clinical responses, prolongation of survival and even cures. More than 20 mAbs have been approved for human use targeting a range of different cancers. However, a major drawback of mAb...
| Clasificación: | Libro Electrónico |
|---|---|
| Autor Corporativo: | |
| Otros Autores: | |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
New York, NY :
Springer New York : Imprint: Springer,
2013.
|
| Edición: | 1st ed. 2013. |
| Colección: | Resistance to Targeted Anti-Cancer Therapeutics,
2 |
| Temas: | |
| Acceso en línea: | Texto Completo |
Tabla de Contenidos:
- Preface
- Introduction and generation of chimeric and humanized mAbs
- mAbs targeted against cancer cells and antibodies targeted against the tumor microenvironment
- Antibodies directed against different major cancers: Effects when used alone or in combination with drugs
- Mechanisms of antibodies-mediated responses, in vitro and in vivo
- Molecular Pathways
- Molecular Signatures
- Identification of resistance targets for intervention
- Various chemicals that can sensitize resistant tumor cells
- Other mAbs
- Proteasome inhibitors
- Divalent mAbs
- Antibodies coupled to chemical inhibitors
- Antibodies coupled to cytokines
- Nanoparticles with mAbs
- Index.